Poïesis Therapeutics is a biotechnology start-up focused on sourcing and in-licensing innovative late stage therapeutics and diagnostics from human biomedical research and developing them to address unmet needs in the veterinary market for pets – dogs, cats and horses.
Our mission statement adheres to the “one health” concept, reflective of the inherent synergies between animal and human medicine.
Developing new medicines to address unmet needs in animal health.
Developing new veterinary diagnostics to identify disorders in dogs, cats and horses.
Corporate Social Responsibility
Poïesis contributes a percentage of its profits to chosen charities which are making a difference for humans and animals.
Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market. By Jenny Rood | October 1, 2016. Around Christmas 2010, University of Minnesota researcher Mark Suckow received terrible news:...read more
Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals
Purchase price of US$6.72 per share, or approximately US$85 million in aggregate Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually 1 PARSIPPANY, N.J. & TULLAMORE,...read more
By Mary Guiden, Communications Coordinator, CSU. Through its clinical trials for animal patients, Colorado State University helped prove the usefulness of the first drug approved by the FDA for treatment of canine lymphoma, a breakthrough in veterinary oncology that...read more
Provides Hope for Humans When Krista DeZerega-Thomson got the dreaded news that Rohan, the family’s beloved Labrador retriever, had cancer, she was devastated. He had metastatic melanoma—an aggressive form that affects dogs and humans—and was given only two months to...read more
Fred, a 6-year-old male shepherd cross, was diagnosed by his referring veterinarian with cancer in his left forelimb in April 2016. Due to preexisting orthopedic issues, he was not a candidate for the traditional amputation and chemotherapy treatment. Faced with only...read more
Baylor Researchers Receive Grant to Study Canine Cancer, Test New Therapies for Translation to Human Cancers
Researchers at Baylor College of Medicine have been awarded a $500,000 grant from the National Institutes of Health that will increase our understanding about the interactions between cancer and the immune system in dogs with naturally occurring tumors. The grant...read more
By Arlene Weintraub, FiercePharma, September 30, 2016. Animal health has long been considered a safe investment, because even during tough economic times, most pet owners don’t scrimp on spending when it comes to keeping their dogs and cats healthy. And the food side...read more
By Helaine Olen, Slate, September 27, 2016. Pets certainly know how to sink their teeth into a household budget. In 2015, my poodle’s long-lasting stomach virus set my family back by almost four figures. Later in the year we got an even heftier bill for a canine root...read more
Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal Allergan could pay up to 19 times the value of the liver-disease treatment maker
NOTE: Poïesis is thrilled to announce that Laurent Fischer, MD, CEO of Tobira Therapeutics and an Advisor to the company has just presided over the acquisition of Tobira by Allergan plc for $1.7 Billion! By Tess Stynes, The Wall Street Journal, September 20, 2016....read more
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.